Octavio Espinoza - 28 Aug 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role: Chief Financial Officer
Signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Octavio Espinoza
Issuer symbol: LGND
Transactions as of: 28 Aug 2024
Net transactions value: +$50,086
Form type: 4
Filing time: 30 Aug 2024, 21:00:59 UTC
Previous filing: 02 Jul 2024
Next filing: 19 Sep 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	LGND	Common Stock	Options Exercise	$11,845	+207	+0.88%	$57.22	23,853	28 Aug 2024	Direct
transaction	LGND	Common Stock	Options Exercise	$38,242	+546	+2.3%	$70.04	24,399	28 Aug 2024	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LGND	Employee Stock Option (right to buy)	Options Exercise	$0	-207	-2.8%	$0.000000	7,309	28 Aug 2024	Common Stock	207	$57.22	Direct	F1
transaction	LGND	Incentive Stock Option (right to buy)	Options Exercise	$0	-546	-100%	$0.000000	0	28 Aug 2024	Common Stock	546	$70.04	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The stock option vests and is exercisable as to approximately 14% of the underlying shares on April 1, 2021, approximately 73% of the underlying shares in 32 substantially equal monthly installments on May 5, 2021, and approximately 13% of the underlying shares in 10 substantially equal monthly installments thereafter.
F2	As per the separation of OmniAb Inc. from the issuer, 402 stock options were vested and exercisable as of November 1, 2022, whereas 144 options vest in 3 substantially equal monthly installments beginning on December 1, 2022.